PDS Biotechnology Corporation Common Stock AGM 2026

Morning. I am Frank Bedu-Addo, President and Chief Executive Officer of the company. Let me take this opportunity to welcome you to the 2026 annual meeting of stockholders of PDS Biotechnology Corporation. This year's annual meeting is again being held in a virtual-only meeting format. This allows stockholders, regardless of physical location, to participate in today's meeting. Not only can you listen to the meeting, but you can also submit questions and vote your shares online prior to the closing of the polls in accordance with the instructions you received prior to the meeting. The polls are now open. The purpose of today's meeting is to consider the following proposals. One, to elect two Class B directors. Two, to approve an amendment to the company's eighth amended and restated certificate of incorporation.

Three, to ratify the appointment of KPMG LLP as the company's independent registered public accounting firm for the fiscal year 2026. Four, to approve, by non-binding advisory vote, the compensation of our named executive officers. At this time, I would like to introduce you to the officers and directors of the company in attendance via phone. Let me first introduce the current directors of the company. Stephen Glover, Chairman of the Board and chair of the compensation committee. Gregory Freitag, chair of the audit committee. Kamil Ali-Jackson, chair of the nominating and corporate governance committee. Ilian Iliev, PhD, Otis Brawley, MD, and myself, Frank Bedu-Addo. I would also like to introduce you to members of our senior management team who are also joining us virtually. Dr. Gregory Conn, Chief Scientific Officer. Dr. Kirk Shepard, MD, Chief Medical Officer. Lars Boesgaard, Chief Financial Officer. Stephan Toutain, Chief Operations Officer.

Spencer Brown, Senior Vice President and General Counsel. Also present at the meeting is Michael Guernsey of KPMG LLP, the company's independent registered public accountants. Also with us today is Fahd Riaz of DLA Piper US LLP, external counsel to the company. We will get started with the technical phase of the meeting in a few moments. First, we would like to direct your attention to the rules of conduct, a copy of which has been posted to the online meeting portal. Among other items, the rules of conduct describe the procedures for asking questions at the meeting. We will only respond to questions related to the official business of the meeting. If you wish to ask a question, please type your question in the Ask a Question section on the left-hand of your screen. You may also ask questions at any point during the meeting.

If your question relates to one of the proposals before the meeting, we will do our best to respond to your question prior to the polls closing. Approximately 15 minutes have been set aside at the end of the meeting for a question and answer session. Please note that the representatives from KPMG LLP will be available to respond to questions raised by stockholders during the question and answer session. During the meeting, stockholders participating online are welcome to submit questions through the virtual meeting platform by typing your question into the Ask a Question field and clicking Submit. Questions pertinent to meeting matters will be answered following the formal portion of the meeting, subject to time constraints. We shall now proceed with the business of the day.